SynthesisScientific reports2021
Differences in coagulopathy indices in patients with severe versus non-severe COVID-19: a meta-analysis of 35 studies and 6427 patients.
Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Coagulation biomarkers and coronavirus disease 2019 phenotyping: a prospective cohort study.Thrombosis journal · 2023Article
- The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.International journal of molecular sciences · 2023Review
- The Role of Multidisciplinary Approaches in the Treatment of Patients with Heart Failure and Coagulopathy of COVID-19.Journal of cardiovascular development and disease · 2023Review
- Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement.Annals of hematology · 2023Review
- Thrombin formation via the intrinsic coagulation pathway and von Willebrand factor reflect disease severity in COVID-19.Haematologica · 2023Article
- Peripheral blood mononuclear cell tissue factor (F3 gene) transcript levels and circulating extracellular vesicles are elevated in severe coronavirus 2019 (COVID-19) disease.Journal of thrombosis and haemostasis : JTH · 2023Article
- Acute Neurological Complications of Coronavirus Disease.Neuroimaging clinics of North America · 2023Review
- Integral assays of hemostasis in hospitalized patients with COVID-19 on admission and during heparin thromboprophylaxis.PloS one · 2023Article
- Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients.International journal of hematology · 2022Article
- The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.The Biochemical journal · 2022Review
- Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.Nature reviews. Cardiology · 2022Review
- Role of Acute Thrombosis in Coronavirus Disease 2019.Critical care clinics · 2022Review
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications.The Biochemical journal · 2022Review
- Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes.Diagnostics (Basel, Switzerland) · 2022Review
- Clinical characteristics and mortality predictors of patients with cancer hospitalized by COVID-19 in a pediatric third-level referral center.Frontiers in pediatrics · 2022Article
- Coagulopathies in Intensive Care Medicine: Balancing Act between Thrombosis and Bleeding.Journal of clinical medicine · 2021Review
- Immature platelets in COVID-19 infection.British journal of haematology · 2021Article
- Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic.Journal of thrombosis and thrombolysis · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a highly contagious disease that appeared in China in December 2019 and spread rapidly around the world. Several patients with severe COVID-19 infection can develop a coagulopathy according to the ISTH criteria for disseminated intravascular coagulopathy (DIC) with fulminant activation of coagulation, resulting in widespread microvascular thrombosis and consumption of coagulation factors. We conducted a meta-analysis in order to explore differences in coagulopathy indices in patients with severe and non-severe COVID-19. An electronic search was performed within PubMed, Google Scholar and Scopus electronic databases between December 2019 (first confirmed Covid-19 case) up to April 6th, 2020. The primary endpoint was the difference of D-dimer values between Non-Severe vs Severe disease and Survivors vs Non-Survivors. Furthermore, results on additional coagulation parameters (platelet count, prothrombin time, activated partial thromboplastin time) were also analyzed. The primary analysis showed that mean d-dimer was significantly lower in COVID-19 patients with non-severe disease than in those with severe (SMD - 2.15 [- 2.73 to - 1.56], I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.